Moreover, EpiVacCorona has not however entered greater medical trials very important to search out out safety and efficacy. Normally, information from late-stage medical trials (Half III trials) are required for regular regulatory approval. These trials are prone to comprise tens of 1000’s of members, who’re fastidiously adopted for months to judge how environment friendly the vaccine is at stopping an an infection and to watch for unusual side-effects.
Nonetheless, Putin touted the model new vaccine inside the info conference, revealing that Deputy Prime Minister Tatyana Golikova and the head of Russia’s consumer safety watchdog Anna Popova have every been given doses of EpiVacCorona as part of a medical trial.
The dearth of data on EpiVacCorona echoes what was seen in August, when Russia licensed its first COVID-19 vaccine, Sputnik V. That vaccine was moreover licensed with out printed information after being examined in solely 76 people. Early trial outcomes have since been launched on the vaccine, nevertheless researchers shortly well-known oddities inside the information. Sputnik V is now in large, Half III trials.
And, like EpiVacCorona, Putin launched the approval of Sputnik V whereas noting early, high-profile vaccinations. Putin revealed that one amongst his private daughters had obtained a dose of the vaccine.